Literature DB >> 24886766

Factor XI as a target for antithrombotic therapy.

Charles E Bane1, David Gailani2.   

Abstract

Anticoagulants currently used in clinical practice to treat thromboembolic disorders are effective but increase the risk of severe bleeding because they target proteins that are essential for normal coagulation (hemostasis). Drugs with better safety profiles are required for prevention and treatment of thromboembolic disease. Coagulation factor XIa has emerged as a novel target for safer anticoagulant therapy because of its role in thrombosis and its relatively small contribution to hemostasis.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24886766      PMCID： PMC4167190          DOI： 10.1016/j.drudis.2014.05.018

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN： 1359-6446            Impact factor:   7.851


  36 in total

1.  High levels of coagulation factor XI as a risk factor for venous thrombosis.

Authors:  J C Meijers; W L Tekelenburg; B N Bouma; R M Bertina; F R Rosendaal
Journal:  N Engl J Med       Date:  2000-03-09       Impact factor: 91.245

2.  Factor XII inhibition reduces thrombus formation in a primate thrombosis model.

Authors:  Anton Matafonov; Philberta Y Leung; Adam E Gailani; Stephanie L Grach; Cristina Puy; Qiufang Cheng; Mao-Fu Sun; Owen J T McCarty; Erik I Tucker; Hiroaki Kataoka; Thomas Renné; James H Morrissey; Andras Gruber; David Gailani
Journal:  Blood       Date:  2014-01-09       Impact factor: 22.113

3.  Tetrahydroquinoline derivatives as potent and selective factor XIa inhibitors.

Authors:  Mimi L Quan; Pancras C Wong; Cailan Wang; Francis Woerner; Joanne M Smallheer; Frank A Barbera; Jeffrey M Bozarth; Randi L Brown; Mark R Harpel; Joseph M Luettgen; Paul E Morin; Tara Peterson; Vidhyashankar Ramamurthy; Alan R Rendina; Karen A Rossi; Carol A Watson; Anzhi Wei; Ge Zhang; Dietmar Seiffert; Ruth R Wexler
Journal:  J Med Chem       Date:  2014-01-17       Impact factor: 7.446

4.  Factor XI anion-binding sites are required for productive interactions with polyphosphate.

Authors:  Y Geng; I M Verhamme; S A Smith; Q Cheng; M Sun; J P Sheehan; J H Morrissey; D Gailani
Journal:  J Thromb Haemost       Date:  2013-11       Impact factor: 5.824

5.  Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits.

Authors:  Jonathan W Yau; Peng Liao; James C Fredenburgh; Alan R Stafford; Alexey S Revenko; Brett P Monia; Jeffrey I Weitz
Journal:  Blood       Date:  2014-02-05       Impact factor: 22.113

6.  Desmolaris, a novel factor XIa anticoagulant from the salivary gland of the vampire bat (Desmodus rotundus) inhibits inflammation and thrombosis in vivo.

Authors:  Dongying Ma; Daniella M Mizurini; Teresa C F Assumpção; Yuan Li; Yanwei Qi; Michail Kotsyfakis; José M C Ribeiro; Robson Q Monteiro; Ivo M B Francischetti
Journal:  Blood       Date:  2013-10-24       Impact factor: 22.113

7.  Evidence for factor IX-independent roles for factor XIa in blood coagulation.

Authors:  A Matafonov; Q Cheng; Y Geng; I M Verhamme; O Umunakwe; E I Tucker; M-F Sun; V Serebrov; A Gruber; D Gailani
Journal:  J Thromb Haemost       Date:  2013-12       Impact factor: 5.824

8.  High levels of factor IX increase the risk of venous thrombosis.

Authors:  A van Hylckama Vlieg; I K van der Linden; R M Bertina; F R Rosendaal
Journal:  Blood       Date:  2000-06-15       Impact factor: 22.113

Review 9.  Novel oral anticoagulants: a review of new agents.

Authors:  Matthew A Wanat
Journal:  Postgrad Med       Date:  2013-07       Impact factor: 3.840

10.  Analysis of the factor XI variant Arg184Gly suggests a structural basis for factor IX binding to factor XIa.

Authors:  Y Geng; I M Verhamme; M F Sun; S P Bajaj; J Emsley; D Gailani
Journal:  J Thromb Haemost       Date:  2013-07       Impact factor: 5.824
View more
  9 in total

1.  Heparan sulfate/heparin glycosaminoglycan binding alters inhibitory profile and enhances anticoagulant function of conserved Amblyomma americanum tick saliva serpin 19.

Authors:  Željko M Radulović; Albert Mulenga
Journal:  Insect Biochem Mol Biol       Date:  2016-11-12       Impact factor: 4.714

Review 2.  Factor XIa inhibitors: A review of the patent literature.

Authors:  Rami A Al-Horani; Umesh R Desai
Journal:  Expert Opin Ther Pat       Date:  2016       Impact factor: 6.674

3.  Structural Basis for Activity and Specificity of an Anticoagulant Anti-FXIa Monoclonal Antibody and a Reversal Agent.

Authors:  Lauren K Ely; Marco Lolicato; Tovo David; Kate Lowe; Yun Cheol Kim; Dharmaraj Samuel; Paul Bessette; Jorge L Garcia; Thomas Mikita; Daniel L Minor; Shaun R Coughlin
Journal:  Structure       Date:  2018-01-11       Impact factor: 5.006

4.  Allosteric Partial Inhibition of Monomeric Proteases. Sulfated Coumarins Induce Regulation, not just Inhibition, of Thrombin.

Authors:  Stephen Verespy; Akul Y Mehta; Daniel Afosah; Rami A Al-Horani; Umesh R Desai
Journal:  Sci Rep       Date:  2016-04-07       Impact factor: 4.379

5.  Effects of Itraconazole and Diltiazem on the Pharmacokinetics and Pharmacodynamics of Milvexian, A Factor XIa Inhibitor.

Authors:  Vidya Perera; Zhaoqing Wang; Susan Lubin; Lisa J Christopher; Wei Chen; Sophia Xu; Dietmar Seiffert; Mary DeSouza; Bindu Murthy
Journal:  Cardiol Ther       Date:  2022-05-31

6.  Blocking domain 6 of high molecular weight kininogen to understand intrinsic clotting mechanisms.

Authors:  Pradeep K Singh; Zu-Lin Chen; Katharina Horn; Erin H Norris
Journal:  Res Pract Thromb Haemost       Date:  2022-10-13

7.  Factor XI Deficiency Alters the Cytokine Response and Activation of Contact Proteases during Polymicrobial Sepsis in Mice.

Authors:  Charles E Bane; Ivan Ivanov; Anton Matafonov; Kelli L Boyd; Qiufang Cheng; Edward R Sherwood; Erik I Tucker; Stephen T Smiley; Owen J T McCarty; Andras Gruber; David Gailani
Journal:  PLoS One       Date:  2016-04-05       Impact factor: 3.240

8.  Fragment-Based Lead Generation of 5-Phenyl-1H-pyrazole-3-carboxamide Derivatives as Leads for Potent Factor Xia Inhibitors.

Authors:  Qunchao Wei; Zhichao Zheng; Shijun Zhang; Xuemin Zheng; Fancui Meng; Jing Yuan; Yongnan Xu; Changjiang Huang
Journal:  Molecules       Date:  2018-08-10       Impact factor: 4.411

9.  The role of haematological traits in risk of ischaemic stroke and its subtypes.

Authors:  Eric L Harshfield; Matthew C Sims; Matthew Traylor; Willem H Ouwehand; Hugh S Markus
Journal:  Brain       Date:  2020-01-01       Impact factor: 13.501
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.